SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dumb SEND IT

Dumb SEND IT ($DSIT) is gaining traction as a high-volatility meme coin on the Solana network, with community members actively discussing its potential for a weekend rally and coordinated "dumb sends" to drive market cap growth. Supporters are highlighting the active involvement of the developer, who is incentivizing engagement through periodic airdrops to holders while encouraging the community to ignore market dips and focus on long-term accumulation.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing increased social media attention as the community debates its long-term potential following recent academic recognition for its post-quantum security architecture. Investors are actively discussing the project's institutional utility and price action, with many using the current market movement as an opportunity to accumulate tokens while others remain skeptical about the asset's historical performance.

"What's Updog?" is a Community Led token.

UpDog

UpDog is generating significant community buzz through its long-standing presence on the Solana network, with holders actively promoting its organic growth and whale accumulation trends. The community remains highly engaged by leveraging the project's playful 'dad joke' branding to maintain visibility and momentum across various social platforms.

Nomad Foods Ltd. operates as a holding company, which manufactures and sells frozen foods for human consumption. The firm offers its products under the brands LUTOSA, la Cocinera, Birds Eye, Iglo, and Findus. The company was founded by Noam Gottesman and Sir Martin E. Franklin on April 1, 2014 and is headquartered in Woking, the United Kingdom.

Nomad Foods Limited

Nomad Foods is trending as investors weigh its attractive dividend yield, aggressive share buyback programs, and low valuation against sector-wide headwinds and concerns about debt levels. The community is actively debating whether these factors signal a deep-value opportunity or a long-term value trap in the frozen food space.

MGM Resorts International is a holding company, which engages in the ownership and operations of casino resorts. The firm's casino resorts offer gaming, hotel, convention, dining, entertainment, retail, and other resort amenities. It operates through the following business segments: Las Vegas Strip Resorts, Regional Operations, MGM China, and MGM Digital. The Las Vegas Strip Resorts segment operates the following casino resorts: Bellagio, MGM Grand Las Vegas, Mandalay Bay, The Mirage, Luxor, New York-New, Excalibur, Park MGM, and Circus Las Vegas. The Regional Operations segment consists of the following casino resorts: MGM Grand Detroit in Detroit, Michigan, Beau Rivage in Biloxi, Mississippi, Gold Strike Tunica in Tunica, Mississippi, Borgata in Atlantic City, New Jersey, MGM National Harbor in Prince George’s County, Maryland, and MGM Springfield in Springfield, Massachusetts. The MGM China segment includes MGM Macau and MGM Cotai. The MGM Digital segment focuses on the online gaming portfolio, which consists primarily of Leo Vegas, which is headquartered in Sweden and Malta. The company was founded by Kerkor Kerkorian on January 29, 1986 and is headquartered in Las Vegas, NV.

MGM Resorts International

MGM Resorts International is drawing attention following the submission of a significant 2.3 billion dollar proposal for a new casino license in New York, a move seen by the community as a key strategy to expand its East Coast footprint. While investors weigh this regulatory catalyst against broader economic concerns, discussions remain split between the stock's long-term potential in the gaming sector and the immediate impact of market-wide volatility on consumer discretionary spending.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is currently seeing intense community activity driven by speculative interest in smaller memecoins and ecosystem tokens, with traders closely monitoring its price action against broader market volatility. Investors are actively debating the potential for long-term growth versus short-term price stagnation, fueled by ongoing discussions around staking incentives and the platform's role in the evolving RWA and memecoin landscapes.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

AIRCOIN is gaining attention for its focus on long-term conviction, with the community actively highlighting deep on-chain liquidity locks and a treasury-backed model that distinguishes it from short-lived memecoin trends. Investors are coalescing around the project's 'PvE' (Player vs. Everyone) narrative, emphasizing high holder retention and the team's track record as key drivers of stability.

Orca is the most user-friendly DEX on Solana.  Orca is one of the first general-purpose AMMs launched on Solana. Users can swap assets, provide liquidity, and earn yield through an easy-to-use interface. Projects can use Orca as a money-lego to easily integrate swapping, farming, or on-chain data into their dApp.  Orca strives to provide easy and effective financial tools for everyone, bringing DeFi to the masses.

Orca

Orca is experiencing significant volatility driven by a short squeeze following recent market events and high trading volume. The community is actively debating the token's upside potential within the Solana ecosystem, with many investors highlighting its role as a key decentralized exchange while others urge caution regarding pump-and-dump dynamics.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is attracting intense community attention as traders speculate on the potential passage of the Clarity Act, which proponents believe will solidify the token's status as a digital commodity and unlock its utility for institutional payments. While many users remain optimistic about the project's long-term infrastructure role, the discussion is polarized by deep frustration over prolonged price stagnation, accusations of artificial volume manipulation, and skepticism regarding the timing of enterprise adoption.

Jupiter is a cryptocurrency exchange platform on the Solana blockchain, offering features such as token swapping, limit orders, dollar-cost averaging, and a bridge for asset transfers to Solana. It provides users with tools to find the best trading prices and includes a beta version for perpetual futures trading. Jupiter finds the best price route for your swap by aggregating all the major liquidity sources on Solana.

Jupiter

The community is actively rallying behind the Jupiter (JUP) ecosystem, with significant focus on the UPDOG meme token as it highlights its presence on the JUP strict list. Participants are emphasizing long-term community resilience and strategic accumulation while leveraging the platform's liquidity tools for trading.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of "Hold" from Brokerages

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) has been given an average rating of "Hold" by the seven brokerages that are presently covering the company, Marketbeat reports. One...

Zentalis Pharmaceuticals, Inc. $ZNTL Shares Acquired by JPMorgan Chase & Co.

JPMorgan Chase & Co. increased its holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 31.4% during the third quarter, according to its most recent filing with the Securities...

Pharmaceutical Stocks To Follow Today - April 10th

Eli Lilly and Company, Abbott Laboratories, Pfizer, AbbVie, Novo Nordisk A/S, Organon & Co., and Zentalis Pharmaceuticals are the seven Pharmaceutical stocks to watch today, according to MarketBeat's...

What's Behind The Surge In Zentalis Stock?

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) shares are surging Friday after a Guggenheim analyst raised the price target from $6 to $10.read more...

<ul class="summary-bullets"><li>Zentalis selected the 400 mg dose of its drug to treat ovarian cancer after it showed a higher response rate than the 300 mg dose.</li><li>The company expects to complete enrollment and report topline results from the trial by the end of 2026.</li><li>This comes just two weeks after the FDA approved Cort’s ovarian cancer treatment months ahead of schedule.</li></ul>Shares of Zentalis Pharmaceuticals (ZNTL) soared over 40% on Friday to their highest level since June 2024, after a bullish analyst call highlighted improved efficacy from a higher dose of its ovarian cancer drug while maintaining a comparable safety profile.Guggenheim raised Zentalis’ price target to $10 from $6 and maintained a ‘Buy’ rating, according to The Fly. This implies a potential 56% upside from the stock’s current price. The firm cited the price target change to the increased confidence in the drug’s chances of success in platinum-resistant ovarian cancer.<h2 class="st-heading-2">Zentalis Picks 400 MG Dose For Future Trials</h2>On Thursday, Zentalis announced encouraging interim results from its DENALI Part 2a study of Azenosertib, an oral therapy, in platinum-resistant ovarian cancer, supporting the drug’s further late-stage development.The biotech firm selected the 400 mg once-daily dose (five days on, two days off) after it showed a clearly higher response rate than the 300 mg dose, while maintaining a similar safety profile. The 400 mg dose will now be used in the ongoing Phase 2 DENALI trial and the Phase 3 ASPENOVA study.Zentalis expects to complete enrollment and report topline results from the DENALI Part 2 trial by the end of 2026.<h2 class="st-heading-2">FDA Approved Corcept’s Ovarian Cancer Drug Months Ahead Of PDUFA Date</h2>The results are crucial, as they allow Zentalis to move towards potential regulatory approval. Just two weeks earlier, the U.S. Food and Drug Administration (FDA) <a href="https://stocktwits.com/news-articles/markets/equity/cort-stock-skyrockets-35-after-early-fda-nod-for-ovarian-cancer-drug/cZ3YMziRISr">approved</a> Corcept Therapeutics’ (CORT) ovarian cancer treatment.The approval covers adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have previously received treatment.Notably, the FDA’s decision came way ahead of schedule, as the therapy had been assigned a Prescription Drug User Fee Act (PDUFA) target date of July 11, 2026.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/ZNTL">ZNTL</a> on Stocktwits changed to ‘extremely bullish’ from ‘bullish,’ amid ‘extremely high’ message volumes.One user expects the company’s valuation to explode seven to 10-fold if the drug is successful in monotherapy.<stembedurl>https://stocktwits.com/Lukey63/message/649876699</stembedurl>However, another user said the stock is overvalued, highlighting the company’s pipeline.<stembedurl>https://stocktwits.com/ScorpionScarlet/message/649934768</stembedurl>Year-to-date, the stock has shot up more than 370%.&nbsp;

On Monday, Deutsche Bank said CAR’s downgrade to ‘Hold’ from ‘Buy' is "purely fundamental in nature"

This Small-Cap Biotech Stock Just Hit A Near 22-Month High – But This Analyst Still Expects Another 56% Rally

Guggenheim raised Zentalis’ price target to $10 from $6 and maintained a ‘Buy’ rating after the company posted the interim results for its ovarian cancer drug.

ZNTL Stock Rallies To Near 22-Month Highs – An Analyst Sees Further 56% Upside After A Crucial Trial Update

Equity

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target Raised to $10.00

Guggenheim lifted their target price on shares of Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the company a "buy" rating in a research note on Friday...

These Stocks are Heating Up Fast

Top stocks to trade this afternoon. $ONCO, $KBLB, $ARAI, $EOSE, $ZNTL

Brokers Issue Forecasts for ZNTL FY2030 Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Equities research analysts at HC Wainwright issued their FY2030 earnings estimates for Zentalis Pharmaceuticals in a report released on...

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Downgraded by Wall Street Zen to "Sell"

Wall Street Zen cut Zentalis Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday...

Zentalis Pharmaceuticals' (ZNTL) "Buy" Rating Reiterated at Guggenheim

Guggenheim reaffirmed a "buy" rating and issued a $6.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday...

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Current Price	$3.98
Prev Close	$3.89
Open	$3.85
Dividend Yield	0.00%
50-Day Moving Average	$3.05
Beta	1.68
Avg. Volume	631,365.14
PE Ratio	-2.09

52-Week High	$6.95
52-Week Low	$1.13
Market Capitalization	$282.31M
EPS (Annual)	-$1.91
Price to Book	1.27
Revenue Per Employee	$0.00

ZNTL
Zentalis Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ZNTL News

ZNTLZentalis Pharmaceuticals Inc